Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monkhorst

Showing results (111-120 of 160) with videos related to

Pageof 16
Sort By:
Neuro-Oncology|August 7, 2024
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases studyJ W Tijmen van der Wel, Mirjam C Boelens, Merel Jebbink, et al.
Nature Medicine|July 9, 2021
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancerPaula Voabil, Marjolein de Bruijn, Lisanne M Roelofsen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2019
Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breathR de Vries, M Muller, V van der Noort, et al.
Interactive Cardiovascular and Thoracic Surgery|November 4, 2021
Importance of tumour volume and histology in trimodality treatment of patients with Stage IIIA non-small cell lung cancer-results from a retrospective analysisPieter J M Joosten, Chris Dickhoff, Vincent van der Noort, et al.
Oncotarget|June 9, 2016
Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifenMaurice Phm Jansen, John Wm Martens, Jean Ca Helmijr, et al.
Cell Reports|July 5, 2016
Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in PatientsEkaterina A Semenova, Min-Chul Kwon, Kim Monkhorst, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 20, 2019
Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohortErik Thunnissen, Keith M Kerr, Urania Dafni, et al.
Nature Medicine|January 26, 2023
Persistent mutation burden drives sustained anti-tumor immune responsesNoushin Niknafs, Archana Balan, Christopher Cherry, et al.
BMC Medical Genomics|November 10, 2020
Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE)Kris G Samsom, Linda J W Bosch, Luuk J Schipper, et al.
ESMO Open|December 4, 2022
Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnosticsL J Schipper, K G Samsom, P Snaebjornsson, et al.
Pageof 16

Showing results (111-120 of 160) with videos related to

Sort By:
Pageof 16
Neuro-Oncology|August 7, 2024
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases studyJ W Tijmen van der Wel, Mirjam C Boelens, Merel Jebbink, et al.
Nature Medicine|July 9, 2021
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancerPaula Voabil, Marjolein de Bruijn, Lisanne M Roelofsen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2019
Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breathR de Vries, M Muller, V van der Noort, et al.
Interactive Cardiovascular and Thoracic Surgery|November 4, 2021
Importance of tumour volume and histology in trimodality treatment of patients with Stage IIIA non-small cell lung cancer-results from a retrospective analysisPieter J M Joosten, Chris Dickhoff, Vincent van der Noort, et al.
Oncotarget|June 9, 2016
Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifenMaurice Phm Jansen, John Wm Martens, Jean Ca Helmijr, et al.
Cell Reports|July 5, 2016
Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in PatientsEkaterina A Semenova, Min-Chul Kwon, Kim Monkhorst, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 20, 2019
Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohortErik Thunnissen, Keith M Kerr, Urania Dafni, et al.
Nature Medicine|January 26, 2023
Persistent mutation burden drives sustained anti-tumor immune responsesNoushin Niknafs, Archana Balan, Christopher Cherry, et al.
BMC Medical Genomics|November 10, 2020
Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE)Kris G Samsom, Linda J W Bosch, Luuk J Schipper, et al.
ESMO Open|December 4, 2022
Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnosticsL J Schipper, K G Samsom, P Snaebjornsson, et al.
Pageof 16